This supplement to The American Journal of Managed Care includes review articles describing different aspects of the diagnosis and treatment of multiple sclerosis (MS). These articles include information on the importance of the early diagnosis and treatment of MS; the favorable outcomes associated with early initiation of disease-modifying therapy (DMT) in patients with MS; the use of comparative effectiveness research by physicians and payers to guide the clinical use and coverage, respectively, of different DMTs; and the role of new and emerging DMTs in the treatment of MS. These articles provide a general overview of some of the key factors involved in the selection and clinical use of DMTs for MS: timing of treatment, available DMTs, and the comparative effectiveness of those DMTs.This supplement was supported by .
Editorial support for the writing of this supplement was provided by Megan Knagge, PhD, of MedErgy, and was funded by Sanofi-Aventis. The authors retained full editorial control over the content of this supplement.
FacultyLaura E. Happe, PharmD, MPH
Department of Pharmaceutical and Administrative Sciences
Presbyterian College School of Pharmacy
Clinton, South Carolina
Katia Noyes, PhD, MPH
Scientific Director and Professor
Department of Surgery
University of Rochester
Rochester, New York
Bianca Weinstock-Guttman, MD
Professor of Neurology
School of Medicine and Biomedical Sciences
State University of New York at Buffalo
Baird MS Center
Pediatric MS Center of Excellence
Jacobs Neurological Institute
Buffalo, New York
These faculty report relationships with the following organizations:
Bianca Weinstock-Guttman, MD
Speakers’ bureau member/consultant: Acorda Therapeutics; Biogen Idec, Inc; EMD Serono; Genzyme; Mylan; Novartis; Pfizer; Sanofi; Teva Neuroscience, Inc
Grants/research support: Acorda Therapeutics; Biogen Idec, Inc; EMD Serono; Genzyme; Mylan; Novartis; Pfizer; Questcor; Sanofi; Shire; Teva Neuroscience, Inc
Laura E. Happe, PharmD, MPH; and Katia Noyes, PhD, MPH, report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.